Brought to you by 
Neuro-focused start-up Biohaven nets $180mm in oversubscribed IPO on NYSE
19 Jul 2017
Executive Summary
Orphan neurologic disease start-up Biohaven Pharmaceuticals Holding Co. Ltd. netted $180mm in its initial public offering on the New York Stock Exchange of 11.4mm shares (including the overallotment) at $17, above its anticipated range of $14-16 for 8.3mm shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neuro-focused start-up Biohaven nets $180mm in oversubscribed IPO on NYSE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice